Intuitive Surgical stock reacts as Wall Street Zen cuts rating after strong quarter

Published on 09/20/2026 at 14:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intuitive Surgical stock closed at USD 393.33 on Nasdaq on September 18, 2026, roughly 30.6 percent below its 52-week high after a strong Q2 2026 revenue jump of 18.4 percent year over year. Wall Street Zen downgraded the shares to Hold, while the analyst consensus still points to a Moderate Buy rating and a USD 508.68 price target.

Fotorealistischer Operationssaal mit einem generischen Roboterchirurgiesystem mit vier Instrumentenarmen über einem blau drapierten Patienten, helles OP-Licht, unscharfe Chirurgensilhouetten im Hintergrund — Intuitive Surgical US46120E6023 zeigt fotorealistischen generischen OP-Roboter mit vier Armen im sterilen Operationssaal, Illustration mit AI erstellt.

Intuitive Surgical stock (ISIN US46120E6023) closed at USD 393.33 on Nasdaq on September 18, 2026, down 30.6 percent from the USD 566.36 level at the start of the year and well below its one-year high of USD 603.88, according to MarketBeat data on September 20, 2026.MarketBeat The shares are trading closer to the one-year low of USD 328.57, underlining how sentiment has cooled despite robust recent operating figures.

Rating downgrade follows strong Q2 figures

The most immediate catalyst for Intuitive Surgical stock is a fresh rating change: Wall Street Zen has downgraded the shares from Buy to Hold in a report dated September 20, 2026, even as the broader analyst community maintains a positive stance.MarketBeat According to this overview, the consensus remains at Moderate Buy, with 22 Buy ratings, eight Hold ratings and one Sell rating, and a consensus price target of USD 508.68, implying notable upside from the current price.

The downgrade comes even though Intuitive Surgical delivered better-than-expected results in its most recent reported quarter, Q2 2026. In that period, the company generated revenue of USD 2.89 billion, up 18.4 percent year over year, and earnings per share of USD 2.80, beating the consensus estimate of USD 2.48 by USD 0.32 per share.MarketBeat A separate research note highlights that Q2 2026 revenue grew 19 percent to USD 2.89 billion, while U.S. da Vinci procedure growth slowed to 12 percent, raising questions about whether domestic growth is maturing.Drillr For investors, the combination of double-digit top-line growth and moderating procedure expansion has become a key discussion point.

Procedure growth, SP platform and European expansion

Operationally, Intuitive Surgical is pushing its robotics platforms into new indications and geographies, which helps explain why many analysts still see long-term potential despite the recent share-price pullback. In Europe, regulators granted CE marking on September 14, 2026 for transvaginal gynecological procedures using the da Vinci SP system, described as the first such indication globally for a single-port platform engineered for one narrow access point.Ad-hoc-news The clearance widens the company's addressable market in European gynecology and adds another minimally invasive option for surgeons.

The same report notes that second-quarter 2026 figures show the da Vinci SP platform gaining traction: Intuitive Surgical placed 38 SP systems during the quarter, lifting the global installed base to 445 units, while procedure volume on those machines increased 61 percent year over year.Ad-hoc-news Against the broader da Vinci franchise, research commentary highlights that overall Q2 2026 revenue grew 19 percent, but U.S. procedure growth slowed to 12 percent, suggesting that non-U.S. markets and newer platforms such as SP are increasingly important for sustaining high growth rates.Drillr

Looking ahead, Intuitive Surgical continues to project worldwide procedure growth of 13.5 percent to 15.5 percent and has left its operating margin target unchanged, according to the European-focused report.Ad-hoc-news This guidance range sets a benchmark for investors to compare against actual quarterly developments; if U.S. procedure growth remains in the low-teens, stronger expansion in Europe and other regions will be needed to remain within the targeted band.

Analyst consensus, ETF exposure and upcoming earnings date

Despite the Wall Street Zen downgrade, the broader analyst picture for Intuitive Surgical stock remains supportive. The MarketBeat overview shows that, as of September 20, 2026, twenty-two analysts rate the shares Buy, eight rate them Hold and one assigns a Sell rating, with a consensus price target of USD 508.68.MarketBeat Compared with the USD 393.33 closing price on September 18, 2026, this implies a potential upside of around 29 percent if the consensus target were reached.

Intuitive Surgical also features in thematic portfolios focused on medical artificial intelligence, which can add another layer of demand or volatility. A Korean report on a U.S. medical AI exchange-traded fund notes that the product, launched in July of the prior year, invests in 15 U.S.-listed companies tied to medical AI, with holdings including Tempus AI, Recursion Pharmaceuticals, Intellia Therapeutics and Intuitive Surgical.Seoul Economic Daily Such inclusion underscores the company's positioning at the intersection of robotics and AI-driven healthcare, although it also links the stock to sentiment swings in the broader theme.

For the near term, the next scheduled checkpoint for fundamental news is the upcoming quarterly earnings release. According to AltIndex, Intuitive Surgical is expected to report its next earnings on October 19, 2026, with the analyst consensus pointing to earnings per share of USD 1.63 for the next quarter.AltIndex The same overview states that, as of September 20, 2026, Intuitive Surgical stock is trading at USD 393.33, down 2.4 percent over the last three months from USD 402.95, and carrying an AI Score of 50, which AltIndex describes as mixed signals heading into the print.AltIndex

Stock level, valuation context and investor takeaway

From a stock-level perspective, several portals paint a consistent picture of Intuitive Surgical stock trading at USD 393.33 on Nasdaq as of the last completed trading day. MarketBeat records a closing price of USD 393.33 at 4:00 p.m. Eastern Time on September 18, 2026, along with a one-year trading range between USD 328.57 and USD 603.88 and a year-to-date decline of 30.6 percent from USD 566.36.MarketBeat TradingView, meanwhile, lists the current price at USD 393.33, a 2.53 percent gain over the last 24 hours, and a market capitalization of around USD 135.50 billion as of mid-September 2026, alongside a one-year performance of minus 9.58 percent and a beta of 1.21.TradingView

These numbers place Intuitive Surgical stock significantly below its 52-week high of USD 603.88, while still comfortably above the one-year low of USD 328.57, leaving room on both sides of the range depending on how future quarters unfold.MarketBeat The market capitalization above USD 130 billion and the still-strong consensus price target highlight that, even after the recent decline, investors are pricing Intuitive Surgical as a leading player in robotic-assisted surgery with substantial long-term expectations.

For investors, the central tension at this stage is clear: Intuitive Surgical is delivering double-digit revenue and procedure growth, expanding platforms such as da Vinci SP into new indications like European gynecology and projecting worldwide procedure growth of 13.5 percent to 15.5 percent, yet the stock trades roughly 29 percent below the consensus price target and far under its 52-week high.Ad-hoc-news MarketBeat The latest Hold rating from Wall Street Zen crystallizes this debate, signaling greater caution around valuation and growth sustainability even as the underlying business continues to expand.

Intuitive Surgical stock and key data

As of the last completed trading day, Intuitive Surgical stock traded at USD 393.33 on Nasdaq on September 18, 2026, with a one-year range between USD 328.57 and USD 603.88 and a market capitalization around USD 135.50 billion in mid-September 2026; these figures frame the current level for investors assessing the upcoming October 19, 2026 earnings release.